A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract
| Authors: | Rathkopf, D. E.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Steinbrecher, J. E.; Arauz, G.; Curley, T.; Rix, P. J.; Maneval, E. C.; Chen, I.; Fleisher, M.; Landa, J.; Fox, J. J.; Larson, S. M.; Scher, H. I. |
| Abstract Title: | A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC) |
| Meeting Title: | 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 30 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2012 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2012-05-20 |
| Language: | English |
| ACCESSION: | WOS:000318009803343 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2012.30.15_suppl.4548 |
| Notes: | Meeting Abstract: 4548 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
